Effects of Milrinone on Contractility and Cyclic Adenosine Monophosphate Production Induced by β1- and β2-Adrenergic Receptor Activation in Human Myocardium

Clinical Therapeutics

Volumn 29, Issue 8, 2007, Pages 1718-1724

  Carceles, Mafía D ^a   Fuentes, Teodomiro ^a   Aroca, Vicente ^a   Lopez, Jesús ^a   Hernández, Jesús ^b  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Medical School   (Spain)

Author keywords

cAMP; epinephrine; human myocardiurn; milrinone; norepinephrine

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE III INHIBITOR;

ADULT; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENERGY YIELD; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME SYNTHESIS; FEMALE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INOTROPISM; MALE; MITRAL VALVE REPLACEMENT; SAMPLING;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPINEPHRINE; FEMALE; HEART ATRIA; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MILRINONE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 34848837596     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.08.009     Document Type: Article

References (21)

1. Molenaar P., and Parsonage W. Fundamental considerations of beta-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 26 (2005) 368-375
2. Brodde O., Bruck H., and Leineweber K. Cardiac adrenoceptors: Physiological and pathophysiological relevance. J Pharmacol Sci 100 (2006) 323-337
3. Movsesian M. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol 34 (1999) 318-324
4. Anamourlis C., Badenhorst D., Gibbs M., et al. Phosphodiesterase inhibition promotes the transition from compensated hypertrophyto cardiac dilatation in rats. Pflugers Arch 451 (2006) 526-533
5. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109 (2006) 366-398
6. Fischmeister R., and Hartzell H. Regulation of calcium current by Iow-Km cyclic AMP phosphodiesterases in cardiac cells. Mol Pharmacol 38 (1990) 426-433
7. Gilbert E., Hershberger R., Wiechmann R., et al. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 108 (1995) 1524-1532
8. Levy J., Bailey J., and Deeb G. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 73 (2002) 325-330
9. Rochais F., Abi-Gerges A., Homer K., et al. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res 98 (2006) 1081-1088
10. Zerkowski H., Ikezono K., Rohm N., et al. Human myocardial beta-adrenoceptors: Demonstration of both beta 1-and beta 2-adrenoceptors mediating contractile responses to beta-agonists on the isolated right atrium. Naunyn Schmiedebergs Arch Pharmacol 332 (1986) 142-147
11. Sudo T., Tachibana K., Toga K., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isoenzyme activity. Biockem Pkarmacol 59 (2000) 347-356
12. Takeda S., Matsumura J., Ikezaki H., et al. Milrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema. Acta Anaestkesiol Scand 47 (2003) 714-719
13. Juan-Fita M., Vargas M., and Hernandez J. Diazepam enhances inotropic responses to dopamine in rat ventricular myocardium. Anesth Analg 102 (2006) 676-681
14. Multiple comparisons. In: van Belle G., Fisher L., Heagerty P., and Lumley T. (Eds). Biostatistics: A Metkodology for the Health Sciences. 2nd ed. (2004), John Wiley & Sons, New York, NY 520-549
15. Steinberg S. Beta(2)-adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts. J Mol Cell Cardiol 37 (2004) 407-415
16. Bristow M., Hershberger R., Port J., et al. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 35 (1989) 295-303
17. 2+ channels by beta-adrenergic agonists. Proc Nail Acad Sci USA 93 (1996) 295-299
18. Nikolaev V., Bunemann M., Schmitteckert E., et al. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching betal-adrenergic but locally confined beta2-adrenergic receptor-mediated signalling. Circ Res 99 (2006) 1084-1091
19. Cuffe M., Califf R., Adams Jr. K., et al., for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 287 (2002) 1541-1547
20. Communal C., Singh K., Sawyer D., and Colucci W. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: Role of pertussis toxin-sensitive G protein. Circulation 100 (1999) 2210-2212
21. Birks E., Tansley P., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 1873-1884